Technical Analysis for MRKR - Marker Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 4.21 1.20% 0.05
MRKR closed down 4.37 percent on Friday, October 18, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Nov 11

*** please verify all earnings dates ***
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MRKR trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 1.20%
Oversold Stochastic Weakness 1.20%
Wide Bands Range Expansion -3.22%
Oversold Stochastic Weakness -3.22%
Wide Bands Range Expansion -2.32%
Oversold Stochastic Weakness -2.32%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.65%
Inside Day Range Contraction -6.65%
Wide Bands Range Expansion -6.65%
Oversold Stochastic Weakness -6.65%

Older signals for MRKR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
MRKR Chart by TradingView
Basic chart:
Profile
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Medicine Cancer Immunology Treatment Of Cancer Immunotherapy Oncology Immune System Cancer Treatments Cancer Immunotherapy Tumor Virotherapy Cell Therapy Immunotherapies Solid Tumor Hematological Malignancies T Cell
Is MRKR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 8 We Think Marker Therapeutics (NASDAQ:MRKR) Can Afford To Drive Business Growth
Aug 19 27 Stocks Moving in Monday's Pre-Market Session
Aug 15 Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs
Aug 9 50 Healthcare Stocks Moving In Thursday's After-Market Session
Aug 8 Marker Therapeutics EPS beats by $0.01
Aug 8 Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results
Aug 8 Do Insiders Own Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?
Aug 6 Marker Therapeutics Appoints Steve Elms to its Board of Directors
Aug 6 The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Jul 26 Marker's Latest Pancreatic Cancer Data Points To Big Potential In Underserved Market
See more MRKR news...
Indicators
Indicator Value
52 Week High 9.9
52 Week Low 3.97
Average Volume 261,254
200-Day Moving Average 5.8016
50-Day Moving Average 5.1268
20-Day Moving Average 4.812
10-Day Moving Average 4.471
Average True Range 0.3152
ADX 22.04
+DI 14.0746
-DI 26.1389
Chandelier Exit (Long, 3 ATRs ) 5.2744
Chandelier Exit (Short, 3 ATRs ) 5.0456
Upper Bollinger Band 5.7057
Lower Bollinger Band 3.9183
Percent B (%b) 0.14
BandWidth 37.144638
MACD Line -0.3014
MACD Signal Line -0.2516
MACD Histogram -0.0498
Fundamentals Value
Market Cap 42.26 Million
Num Shares 10.2 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -4.08
Price-to-Sales 0.00
Price-to-Book 3.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.61
Resistance 3 (R3) 4.64 4.52 4.54
Resistance 2 (R2) 4.52 4.41 4.51 4.51
Resistance 1 (R1) 4.34 4.33 4.28 4.31 4.48
Pivot Point 4.22 4.22 4.19 4.21 4.22
Support 1 (S1) 4.04 4.11 3.98 4.01 3.84
Support 2 (S2) 3.92 4.03 3.91 3.81
Support 3 (S3) 3.74 3.92 3.79
Support 4 (S4) 3.71